Ernesto Estrada, Samuel Vazquez, Jul 28, 2013
This document studies bid rigging in public procurement of generic drugs in Mexico. The study is based on the outcomes of a series of public auctions for generic drugs held in 52 different locations between 2003 and 2008. By applying price and market share screenings, we identify many drugs where lowest bids tend to be identical across auctions regardless of winner, location or contract volume; and market shares quickly converge over time. Additionally, bids dropped and the above pattern disappeared after aggressive entry or procurement consolidation occurred. These findings triggered a formal investigation by the Mexican antitrust agency of two of the largest families of drugs: insulin and saline solutions. These collusive patterns and other indirect evidence gathered during the investigation, led to issue a decision by the agency of illegal bid rigging in both cases. This decision was challenged before Mexican courts, which confirmed it.
Featured News
Warren Questions McDonald’s CEO Over AI Pricing
Nov 3, 2026 by
CPI
Intesa CEO Confident of Antitrust Clearance for €34 Billion Monte dei Paschi Bid
Nov 3, 2026 by
CPI
EU Clears JD.com’s $2.5 Billion Ceconomy Takeover With Conditions on Chinese Subsidies
Nov 3, 2026 by
CPI
Amazon Faces Antitrust Class Action Involving 10 Million Consumers
Nov 3, 2026 by
CPI
McDonald’s Hires White & Case to Defend Against AI Price-Fixing Suits
Nov 3, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Exclusive Dealing
Oct 25, 2026 by
CPI
Exclusive Dealing Without Exclusivity: Screening Contracts, Loyalty Rebates, and the Limits of Antitrust Tests
Oct 25, 2026 by
David Martimort & Jérôme Pouyet
When Competition for Exclusivity Raises Prices: Rebates, Pricing Rules, and the Insulin Puzzle
Oct 25, 2026 by
Daniel P. O’Brien & Greg Shaffer
Why Leaving the Door Open Can Be (Much) Worse Than Closing It: Share-Based Requirements, Buyer-Specific Costs, and Foreclosure
Oct 25, 2026 by
Zhijun Chen & Greg Shaffer
Antitrust Chronicle® – EU Merger Guidelines
Oct 19, 2026 by
CPI